Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2005.04.5807 on January 23 2006

Journal of Clinical Oncology, Vol 24, No 6 (February 20), 2006: pp. 929-936
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Publisher's Note
Right arrow Erratum (v24,p2687)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barlogie, B.
Right arrow Articles by Crowley, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barlogie, B.
Right arrow Articles by Crowley, J. C.

Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321

Bart Barlogie, Robert A. Kyle, Kenneth C. Anderson, Philip R. Greipp, Hillard M. Lazarus, David D. Hurd, Jason McCoy, Dennis F. Moore, Jr, Shaker R. Dakhil, Keith S. Lanier, Robert A. Chapman, Jeana N. Cromer, Sydney E. Salmon{dagger}, Brian Durie, John C. Crowley

From the University of Arkansas for Medical Science, Little Rock, AR; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; University Hospitals of Cleveland, Cleveland, OH; Wake Forest University School of Medicine, Winston-Salem, NC; Southwest Oncology Group Statistical Center, Seattle, WA; Wichita Community Clinical Oncology Program, Wichita, KS; Columbia River Community Clinical Oncology Program, Portland, OR; Henry Ford Hospital, Detroit, MI; St Jude Children's Research Hospital, Memphis, TN; University of Arizona Cancer Center, Tucson, AZ; and Cedars Sinai Cancer Center, Los Angeles, CA
{dagger} Deceased.

Address reprint requests to the Southwest Oncology Group (SWOG-9321), Operations Office, 14980 Omicron Dr, San Antonio, TX 78245-3217

PURPOSE: Results of a prospective randomized trial conducted by the Intergroupe Francais du Myélome (IFM 90) indicated that autologous hematopoietic cell–supported high-dose therapy (HDT) effected higher complete response rates and extended progression-free survial (PFS) and overall survival (OS) compared with standard-dose therapies (SDT) for patients with multiple myeloma (MM).

PATIENTS AND METHODS: In 1993, three North American cooperative groups launched a prospective randomized trial (S9321) comparing HDT (melphalan [MEL] 140 mg/m2 plus total-body irradiation 12 Gy) with SDT using the vincristine, carmustine, MEL, cyclophosphamide, and prednisone regimen. Responders on both arms (≥ 75%) were randomly assigned to interferon (IFN) or no maintenance treatment.

RESULTS: With a median follow-up time of 76 months, no differences were observed in response rates between the two study arms (HDT, n = 261 patients; SDT, n = 255 patients). Similarly, PFS and OS durations did not differ between the HDT and SDT arms, with 7-year estimates of PFS of 17% and 16%, respectively, and OS of 37% and 42%, respectively. Of 242 patients achieving at least 75% tumor reduction, no difference was observed in PFS or OS among the 121 patients randomly assigned to IFN and the 121 patients randomly assigned to no maintenance therapy. Among 157 patients relapsing on SDT, 87 received a salvage autotransplantation; their median survival time of 30 months was only slightly better than the survival time of the remaining patients who were managed with further SDT (23 months; P = .13).

CONCLUSION: The HDT and SDT regimens used in S9321 yielded comparable response rates and PFS and OS durations. IFN maintenance therapy did not benefit patients who achieved ≥ 75% tumor reduction on either arm.

Supported in part by the following Public Health Service Cooperative Agreement Grants No. awarded by the National Cancer Institute, Department of Health and Human Services: CA38926, CA32102, CA13650, CA14548, CA31946, CA32291, CA03927, CA37981, CA35431, CA45377, CA58416, CA22433, CA58686, CA46113, CA04919, CA46441, CA58861, CA46282, CA35261, CA27057, CA76132, CA35192, CA76447, CA76462, CA45450, CA76429, CA63845, CA12644, CA20319, CA63844, CA45560, CA58415, CA14028, CA58658, CA42777, CA35119, CA35090, CA35117, CA13612, CA16385, CA67575, CA68183, CA46368, CA04920, CA74647, and CA52654; also supported in part by Amgen and Schering.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
BloodHome page
J. Mehta
One or two autografts for myeloma?
Blood, April 1, 2008; 111(7): 3899 - 3900.
[Full Text] [PDF]


Home page
BloodHome page
R. A. Kyle and S. V. Rajkumar
Multiple myeloma
Blood, March 15, 2008; 111(6): 2962 - 2972.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. K. Kumar, S. V. Rajkumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, F. K. Buadi, S. R. Zeldenrust, D. Dingli, S. J. Russell, J. A. Lust, et al.
Improved survival in multiple myeloma and the impact of novel therapies
Blood, March 1, 2008; 111(5): 2516 - 2520.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
J.-P. Fermand
Initial Therapy for Multiple Myeloma: Role of Stem Cell Transplantation
ASCO Educational Book, January 1, 2008; 2008(1): 375 - 379.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Dingli, J. M. Pacheco, G. S. Nowakowski, S. K. Kumar, A. Dispenzieri, S. R. Hayman, M. Q. Lacy, D. A. Gastineau, and M. A. Gertz
Relationship Between Depth of Response and Outcome in Multiple Myeloma
J. Clin. Oncol., November 1, 2007; 25(31): 4933 - 4937.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. A. Dimopoulos, V. L. Souliotis, A. Anagnostopoulos, C. Bamia, A. Pouli, I. Baltadakis, E. Terpos, S. A. Kyrtopoulos, and P. P. Sfikakis
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma
Haematologica, November 1, 2007; 92(11): 1505 - 1512.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
J. A. Katzel, P. Hari, and D. H. Vesole
Multiple Myeloma: Charging Toward a Bright Future
CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y.-T. Tai, M. Fulciniti, T. Hideshima, W. Song, M. Leiba, X.-F. Li, M. Rumizen, P. Burger, A. Morrison, K. Podar, et al.
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
Blood, September 1, 2007; 110(5): 1656 - 1663.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
R. Manochakian, K. C. Miller, and A. A. Chanan-Khan
Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma
Oncologist, August 1, 2007; 12(8): 978 - 990.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
P. Sonneveld, B. van der Holt, C. M. Segeren, E. Vellenga, A. J. Croockewit, G. E.G. Verhoef, J. J. Cornelissen, M. R. Schaafsma, M. H.J. van Oers, P. W. Wijermans, et al.
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
Haematologica, July 1, 2007; 92(7): 928 - 935.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist, June 1, 2007; 12(6): 664 - 689.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Y. Kristinsson, O. Landgren, P. W. Dickman, A. R. Derolf, and M. Bjorkholm
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
J. Clin. Oncol., May 20, 2007; 25(15): 1993 - 1999.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. Bruno, M. Rotta, F. Patriarca, N. Mordini, B. Allione, F. Carnevale-Schianca, L. Giaccone, R. Sorasio, P. Omede, I. Baldi, et al.
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
N. Engl. J. Med., March 15, 2007; 356(11): 1110 - 1120.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau
Stem Cell Transplantation in Multiple Myeloma
Hematology, January 1, 2007; 2007(1): 311 - 316.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
S. Singhal and J. Mehta
Multiple Myeloma
Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1322 - 1330.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M.-V. Mateos, J.-M. Hernandez, M.-T. Hernandez, N.-C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J.-J. Lahuerta, J. de la Rubia, M.-J. Terol, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Blood, October 1, 2006; 108(7): 2165 - 2172.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
I. Hanamura, J. P. Stewart, Y. Huang, F. Zhan, M. Santra, J. R. Sawyer, K. Hollmig, M. Zangarri, M. Pineda-Roman, F. van Rhee, et al.
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Blood, September 1, 2006; 108(5): 1724 - 1732.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online